The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years ...

The US company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.

GN Store Nord A/S was the biggest leader among large stocks during the session, rising 8.4%, and BioGaia AB Series B rose 6.2%. Hemnet Group AB rounded out the top three leaders on Tuesday, with ...

Bavarian Nordic’s stock dropped around 10% on the Danish stock exchange Tuesday after reporting disappointing 2024 sales despite a rise of demand for its mpox vaccines.

COPENHAGEN - Bavarian Nordic A/S (OMX:CSE:BAVA) shares fell 10% after the Danish vaccine maker reported preliminary 2024 results and provided 2025 guidance that failed to impress investors. The ...

Financial guidance for 2025 in line with the Company's 2024-2027 ambitions. COPENHAGEN, Denmark, February 3, 2025 - Bavarian Nordic A/S (OMX: BAVA) today announced preliminary, unaudited financial ...

Travel Health business demonstrated strong growth of 22%.Additional mpox vaccine orders during outbreak drove higher revenues ...

Elkem ASA posted the largest decline among large stocks during the session, dropping 6.4%, followed by Netcompany Group A/S shares, which fell 5.4%. Shares of Bavarian Nordic A/S dropped 5.3%.

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...

If authorised, Vimkunya would be the first vaccine in the EU to protect adolescents aged 12 to 17 against Chikungunya.

Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...